Table 1 Antimalarial drug-resistance mutations in the pre-treatment and post-treatment samples
| Antimalarial drug-resistance markers |
Pre-treatment (n = 60) |
Post-treatment (n = 51) |
Total (n = 111) |
|---|---|---|---|
| No. (%) | No. (%) | No. (%) | |
| pfmdr1 86 | |||
| N | 8 (13.3) | 10 (19.6) | 18 (16.2) |
| Y | 52 (86.7) | 14 (78.4) | 92 (82.9) |
| N/Y | 0 (0.0) | 1 (2.0) | 1 (0.9) |
| pfmdr1 184 | |||
| F | 41 (68.3) | 28 (54.9) | 69 (62.2) |
| Y | 19 (31.7) | 23 (45.1) | 42 (37.8) |
| pfmdr1 1246 | |||
| D | 58 (96.7) | 49 (96.1) | 107 (96.4) |
| Y | 2 (3.3) | 2 (3.9) | 4 (3.6) |
| pfcrt 76 | |||
| K | 1 (1.7) | 5 (9.8) | 6 (5.4) |
| T | 59 (98.3) | 44 (86.3) | 103 (92.8) |
| K/T | 0 (0.0) | 2 (3.9) | 2 (1.8) |
| pfmdr1 86 + 184 + 1246-pfcrt 76 | |||
| YFD-T | 33 (55.0) | 24 (47.1) | 57 (51.4) |
| YYD-T | 16 (26.7) | 14 (27.5) | 30 (27.0) |
| NFD-T | 6 (10.0) | 3 (5.9) | 9 (8.1) |
| YFD-K | 2 (3.3) | 1 (2.0) | 3 (2.7) |
| NYD-K | 0 (0.0) | 3 (5.9) | 3 (2.7) |
| YYY-T | 1 (1.7) | 1 (2.0) | 2 (1.8) |
| NYD-K/T | 0 (0.0) | 2 (3.9) | 2 (1.8) |
| NYD-T | 1 (1.7) | 1 (2.0) | 2 (1.8) |
| NYY-T | 1 (1.7) | 1 (2.0) | 2 (1.8) |
| N/YYD-K | 0 (0.0) | 1 (2.0) | 1 (0.9) |